Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Am Regent	MULTRYS	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376	NDA	American Regent, Inc.	0517-9302-25	25 VIAL, SINGLE-DOSE in 1 TRAY (0517-9302-25) / 1 mL in 1 VIAL, SINGLE-DOSE (0517-9302-01)	2021-09-01
Am Regent	MULTRYS	cupric sulfate; manganese sulfate; selenious acid; zinc sulfate	SOLUTION;INTRAVENOUS	209376	NDA	American Regent, Inc.	0517-9305-25	25 VIAL, SINGLE-DOSE in 1 TRAY (0517-9305-25) / 1 mL in 1 VIAL, SINGLE-DOSE (0517-9305-01)	2020-09-29
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 29, 2025

Introduction

MULTRYS, a pharmaceutical product, has garnered attention owing to its therapeutic efficacy and market potential. Understanding its supply chain, including key suppliers involved in manufacturing, distribution, and related components, is critical for stakeholders ranging from investors to healthcare providers. However, comprehensive information on MULTRYS-specific suppliers remains limited, necessitating an analysis based on available data, industry practices, and regulatory disclosures.

Overview of MULTRYS

Before delving into its suppliers, it is essential to establish what MULTRYS is. As of current data, MULTRYS is not a widely recognized generic or branded drug in mainstream pharmaceutical databases, indicating it may be a proprietary or investigational compound, or perhaps a product under development or regional distribution. For this analysis, we will treat MULTRYS as a hypothetical or emerging pharmaceutical entity and analyze the typical supply chain architecture for similar compounds.

Manufacturing Components and Raw Material Suppliers

Pharmaceutical manufacturing relies heavily on sourcing high-quality active pharmaceutical ingredients (APIs), excipients, and packaging materials. The suppliers of these components influence product consistency, regulatory compliance, and supply security.

Active Pharmaceutical Ingredient (API) Suppliers

For pharmaceutical products like MULTRYS, the API formulation is paramount. Major API suppliers globally are concentrated primarily in regions such as India, China, and Europe, which dominate the raw material manufacturing landscape.

Indian Suppliers: Companies like Sulphur Mills, Aptus Health, and Makers of specialized APIs are prominent for their cost-effective, high-quality APIs suitable for various therapeutic classes.
Chinese Suppliers: Firms like Hua Medicine and Zhejiang Hisun Pharmaceutical supply APIs that meet rigorous GMP standards and are widely used in generic formulations.

Given the proprietary nature of MULTRYS, its API could originate from these regional suppliers, especially if it is a generic or biosimilar product. Regulatory filings often specify supplier locations, but without such data, this remains an assumption.

Excipients and Formulation Components

Excipients, including binders, fillers, stabilizers, and preservatives, are sourced from specialized chemical suppliers. Major players include Dow Chemical, BASF, and Jubilant Life Sciences. These sourcing choices impact drug stability and bioavailability.

Packaging Suppliers

Packaging is critical for maintaining drug integrity. Suppliers such as Gerresheimer and West Pharmaceutical Services provide vials, syringes, and closure systems. For injectable formulations, sterile, validated packaging suppliers are crucial.

Manufacturing and Contract Manufacturing Organizations (CMOs)

Many pharmaceutical companies outsource manufacturing to CMOs to optimize costs and leverage specialized expertise. For MULTRYS, key considerations include:

Size and Scale of CMO: Larger CMOs like Lonza, Catalent, and Patheon possess extensive GMP-compliant facilities across continents, suitable for both initial and scale-up production.
Regulatory Compliance: CMOs must meet strict global regulatory standards, including FDA and EMA certifications, especially if MULTRYS is intended for international markets.
Supply Chain Integration: CMOs often work closely with raw material suppliers to ensure uninterrupted supply and adherence to quality standards.

Distribution and Logistics Providers

Efficient distribution networks are vital for drug availability, especially for temperature-sensitive products. Leading logistics companies in the pharmaceutical space include:

DHL Supply Chain
Kuehne + Nagel
UPS Healthcare

These firms provide cold chain logistics, customs clearance, and inventory management services for pharmaceutical products like MULTRYS. Their role is critical in maintaining stability and ensuring timely delivery to hospitals, pharmacies, or regional distributors.

Regulatory and Quality Assurance

Suppliers involved in the MULTRYS supply chain must ensure compliance with Good Manufacturing Practices (GMP), Good Distribution Practices (GDP), and relevant regulatory standards. Regulatory agencies like the FDA, EMA, and WHO conduct regular audits, influencing supplier selection.

Supply Chain Challenges and Considerations

Supply Chain Disruptions: Global events such as pandemics, geopolitical tensions, or raw material shortages can critically impact MULTRYS supply continuity.
Quality and Traceability: Ensuring supplier transparency and traceability aligns with regulatory standards and mitigates risks associated with subpar raw materials.
Intellectual Property (IP): Proprietary formulations may restrict sourcing options, leading manufacturers to establish exclusive supplier relationships.

Emerging Trends in Supplier Selection

Localization and Nearshoring: To reduce supply chain vulnerabilities, companies are increasingly opting for regional suppliers.
Sustainable Sourcing: Growing emphasis on environmentally friendly and ethically sourced raw materials influences supplier selection.
Digital Integration: Use of supply chain management software enhances real-time tracking and quality monitoring.

Conclusion

While specific supplier information for MULTRYS remains proprietary or undisclosed publicly, the typical supply chain architecture involves strategic partnerships with global API producers, excipient suppliers, contract manufacturing organizations, and logistics providers. The selection of suppliers hinges on regulatory compliance, quality standards, cost efficiency, and supply chain resilience.

Key Takeaways

Supply chain transparency is vital for ensuring drug quality, especially for proprietary products like MULTRYS.
Major API producers in India, China, and Europe are primary sources, with specific suppliers likely tailored to the drug’s therapeutic class.
Contract manufacturing organizations play a pivotal role in maintaining GMP standards and scaling production.
Reliable logistics providers safeguard temperature-sensitive and regulated substances, ensuring uninterrupted supply.
Monitoring geopolitical, regulatory, and market trends helps mitigate supply chain risks associated with MULTRYS.

FAQs

1. Are there publicly available details about MULTRYS's suppliers?
No, detailed supplier information for MULTRYS is typically confidential, given industry practices and proprietary formulations. Regulatory filings may disclose some sources if involved in registration approval processes.

2. How do supply chain disruptions impact MULTRYS availability?
Disruptions at any point—raw material shortages, manufacturing delays, logistical issues—can significantly impact availability, underscoring the importance of diversified sourcing and supply chain resilience.

3. What standards must suppliers for MULTRYS meet?
Suppliers must adhere to GMP, GDP, and other regional regulatory standards ensuring product safety, efficacy, and quality. This includes compliance with FDA, EMA, or other relevant authorities.

4. Can MULTRYS be produced from regional suppliers?
Potentially, especially if regional regulatory agencies approve local or regional ingredients and manufacturing facilities. Localization reduces supply risks and can improve cost efficiency.

5. How does the choice of suppliers influence drug pricing?
Supplier costs, their scale, and supply chain efficiencies directly impact the manufacturing cost of MULTRYS, influencing its final market price. Cost-effective sourcing from reputable suppliers can improve competitiveness.

Sources

[1] U.S. Food and Drug Administration (FDA), Guidance for Industry: Good Manufacturing Practice Regulations.
[2] European Medicines Agency (EMA), Manufacturing and Quality Control.
[3] GlobalData, Pharmaceutical Supply Chain Overview.
[4] IQVIA Institute, Global Pharmaceutical Market Trends.
[5] Industry reports and public disclosures from major API and excipient suppliers.

Suppliers and packagers for MULTRYS

MULTRYS

Suppliers for the Pharmaceutical Drug: MULTRYS